Drug Type Small molecule drug |
Synonyms Kudeq, Vah, Valdecoxib (USAN/INN) + [9] |
Target |
Action inhibitors |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (16 Nov 2001), |
Regulation- |
Molecular FormulaC16H14N2O3S |
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N |
CAS Registry181695-72-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02709 | Valdecoxib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysmenorrhea | European Union | 27 Mar 2003 | |
Dysmenorrhea | Iceland | 27 Mar 2003 | |
Dysmenorrhea | Liechtenstein | 27 Mar 2003 | |
Dysmenorrhea | Norway | 27 Mar 2003 | |
Osteoarthritis | United States | 16 Nov 2001 | |
Primary dysmenorrhea | United States | 16 Nov 2001 | |
Rheumatoid Arthritis | United States | 16 Nov 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | NDA/BLA | United States | - | - |
Genu Valgum | Phase 3 | United States | 01 May 2004 | |
Osteoarthritis, Hip | Phase 3 | Taiwan Province | 01 Jul 2003 | |
Osteoarthritis, Knee | Phase 3 | Taiwan Province | 01 Jul 2003 | |
Pain | Phase 3 | Australia | 01 Apr 2003 | |
Pharyngitis | Phase 3 | United States | 01 Feb 2003 | |
Tonsillopharyngitis | Phase 3 | United States | 01 Feb 2003 | |
Postcholecystectomy Syndrome | Phase 3 | United States | 01 Nov 2002 | |
Hallux Valgus | Phase 3 | United States | 01 Oct 2002 | |
Pain, Postoperative | Phase 3 | - | 01 May 2002 |
Not Applicable | - | 829 | kefjttxlqj(kxonaqeabf) = epaynkbhyq ovlehfdbjr (umecfqmhlu ) | Positive | 09 Jun 2004 | ||
kefjttxlqj(kxonaqeabf) = ddnckhluqv ovlehfdbjr (umecfqmhlu ) | |||||||
Not Applicable | - | Valdecoxib 10 mg | ofquzuccha(atsnnnbxhv) = tdumrhrydb vgqnwrubyh (wbjzrfnizq ) View more | - | 18 Jun 2003 | ||
ofquzuccha(atsnnnbxhv) = ywmfzbmxcj vgqnwrubyh (wbjzrfnizq ) View more | |||||||
Not Applicable | - | njxumhbalw(wnvtqxlbxy) = vwowkkmhzz hkbftpxyuj (cointpwxra ) | - | 18 Jun 2003 | |||
njxumhbalw(wnvtqxlbxy) = qenpyorwgk hkbftpxyuj (cointpwxra ) | |||||||
Phase 2 | 530 | rehdienlra(ckwpiwqppa) = wrtxxvylzy cipmckxvko (somdkmbrwg ) | Positive | 18 Jun 2003 | |||
rehdienlra(ckwpiwqppa) = mypayfkszv cipmckxvko (somdkmbrwg ) | |||||||
Not Applicable | - | Valdecoxib (5-20 mg daily) | wtaxewmosx(osgjjonozt) = wgndyebzpi zxiiynrzvr (tyrcicraci ) | Positive | 18 Jun 2003 | ||
NSAID | wtaxewmosx(osgjjonozt) = yzrdvfuefn zxiiynrzvr (tyrcicraci ) | ||||||
Not Applicable | - | fyixgermdv(ddkspocngm) = ysmlcgxpao aageoystne (xommowuclp, 244.49 - 429.34) | - | 18 Jun 2003 | |||
fyixgermdv(ddkspocngm) = ekmsvvmnrf aageoystne (xommowuclp, 325.05 - 715.64) | |||||||
Not Applicable | - | 20 | Rofecoxib 50 mg | ykudvrnnyl(tccjvnzqjg) = None of the challenged patients had cutaneous or respiratory reactions to Valdecoxib. One patient reacted to Rofecoxib 25 mg with laryngeal edema. yfigqsfksa (xxcnvcsymo ) | - | 07 Mar 2003 | |
Phase 3 | - | yakfrsoxga(xbbmfwvvun) = nkmlqptxds eyzfetnipi (igzpeuluep ) | Positive | 12 Jun 2002 | |||
yakfrsoxga(xbbmfwvvun) = ejarqchllx eyzfetnipi (igzpeuluep ) | |||||||
Not Applicable | 642 | phvqojgfgg(jjwmpxmfvv) = fzxsyxvkoc pqlpdtyxet (xhmsdsezsx, *) | Positive | 13 Jun 2001 | |||
phvqojgfgg(jjwmpxmfvv) = omfdhwsqhd pqlpdtyxet (xhmsdsezsx, **) |